FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597476871> ?p ?o ?g. }

• W2597476871 endingPage "61" @default.
• W2597476871 startingPage "56" @default.
• W2597476871 abstract "BackgroundIpilimumab (IPI) and BRAF inhibitors (BRAFi) improve survival in melanoma, but not all patients will benefit and toxicity can be significant. Pretreatment neutrophil to lymphocyte ratio (NLR) has been associated with outcome in IPI-treated patients, but has not been studied during treatment or in BRAFi-treated patients.MethodsUsing a prospectively maintained database, patients with unresectable stage III or IV melanoma treated with IPI or a BRAFi (vemurafenib or dabrafenib as monotherapy) from 2006 to 2011 were identified. NLR was calculated before treatment and at 3-week intervals after treatment initiation until 9 weeks. Baseline NLR was tested for association with overall survival (OS), progression free survival (PFS), and clinical response to treatment. On-treatment NLRs were tested for association with the same outcomes using landmark survival analyses and time-dependent Cox regression models. The association of relative change of NLR from baseline with outcomes was also examined. A multivariate model tested the association of NLR and OS/PFS with additional clinical factors.ResultsThere were 197 IPI patients and 65 BRAFi patients. In multivariable analysis adjusting for M stage, and disease type (in OS)/gender (in PFS), an NLR value of 5 or above at every timepoint was associated with worse OS (HR 2.03–3.37, p < 0.001), PFS (HR 1.81–2.51, p < 0.001), and response to therapy (OR 3.92–9.18, p < 0.007), in the IPI cohort. In addition, a >30% increase in NLR above baseline at any timepoint was associated with a worse OS and PFS (HR 1.81 and 1.66, p < 0.004). In BRAFi patients, NLR was not consistently associated with outcomes.ConclusionsA high NLR, whether measured prior to or during treatment with IPI, is associated with worse OS, PFS, and clinical response in patients with advanced melanoma. An increasing NLR from baseline during treatment was correlated with worse OS and PFS in IPI-treated patients. In comparison, as NLR was not associated with outcomes in BRAFi patients, NLR may have a uniquely predictive value in patients treated with immunotherapy." @default.
• W2597476871 created "2017-04-07" @default.
• W2597476871 creator A5002954478 @default.
• W2597476871 creator A5002965160 @default.
• W2597476871 creator A5010002970 @default.
• W2597476871 creator A5011325668 @default.
• W2597476871 creator A5014911718 @default.
• W2597476871 creator A5021407180 @default.
• W2597476871 creator A5048552055 @default.
• W2597476871 creator A5054656505 @default.
• W2597476871 date "2017-04-01" @default.
• W2597476871 modified "2023-10-14" @default.
• W2597476871 title "Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment" @default.
• W2597476871 cites W1870093969 @default.
• W2597476871 cites W1919200564 @default.
• W2597476871 cites W1965370740 @default.
• W2597476871 cites W1975475568 @default.
• W2597476871 cites W1976156978 @default.
• W2597476871 cites W1982906652 @default.
• W2597476871 cites W1984052587 @default.
• W2597476871 cites W1992066819 @default.
• W2597476871 cites W1992226123 @default.
• W2597476871 cites W2007961952 @default.
• W2597476871 cites W2033707203 @default.
• W2597476871 cites W2043432815 @default.
• W2597476871 cites W2051820020 @default.
• W2597476871 cites W2078065548 @default.
• W2597476871 cites W2088741578 @default.
• W2597476871 cites W2094798668 @default.
• W2597476871 cites W2097995306 @default.
• W2597476871 cites W2100158834 @default.
• W2597476871 cites W2102031533 @default.
• W2597476871 cites W2111404068 @default.
• W2597476871 cites W2117692326 @default.
• W2597476871 cites W2118982164 @default.
• W2597476871 cites W2121071739 @default.
• W2597476871 cites W2121545342 @default.
• W2597476871 cites W2128035403 @default.
• W2597476871 cites W2128542677 @default.
• W2597476871 cites W2128758225 @default.
• W2597476871 cites W2143163879 @default.
• W2597476871 cites W2159082613 @default.
• W2597476871 cites W2169945437 @default.
• W2597476871 cites W2419296002 @default.
• W2597476871 cites W2517455019 @default.
• W2597476871 cites W2519279652 @default.
• W2597476871 cites W2523880687 @default.
• W2597476871 cites W2560367415 @default.
• W2597476871 cites W2572174216 @default.
• W2597476871 doi "https://doi.org/10.1016/j.ebiom.2017.03.029" @default.
• W2597476871 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5405176" @default.
• W2597476871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28356222" @default.
• W2597476871 hasPublicationYear "2017" @default.
• W2597476871 type Work @default.
• W2597476871 sameAs 2597476871 @default.
• W2597476871 citedByCount "76" @default.
• W2597476871 countsByYear W25974768712017 @default.
• W2597476871 countsByYear W25974768712018 @default.
• W2597476871 countsByYear W25974768712019 @default.
• W2597476871 countsByYear W25974768712020 @default.
• W2597476871 countsByYear W25974768712021 @default.
• W2597476871 countsByYear W25974768712022 @default.
• W2597476871 countsByYear W25974768712023 @default.
• W2597476871 crossrefType "journal-article" @default.
• W2597476871 hasAuthorship W2597476871A5002954478 @default.
• W2597476871 hasAuthorship W2597476871A5002965160 @default.
• W2597476871 hasAuthorship W2597476871A5010002970 @default.
• W2597476871 hasAuthorship W2597476871A5011325668 @default.
• W2597476871 hasAuthorship W2597476871A5014911718 @default.
• W2597476871 hasAuthorship W2597476871A5021407180 @default.
• W2597476871 hasAuthorship W2597476871A5048552055 @default.
• W2597476871 hasAuthorship W2597476871A5054656505 @default.
• W2597476871 hasBestOaLocation W25974768711 @default.
• W2597476871 hasConcept C121608353 @default.
• W2597476871 hasConcept C126322002 @default.
• W2597476871 hasConcept C143998085 @default.
• W2597476871 hasConcept C2776131300 @default.
• W2597476871 hasConcept C2777701055 @default.
• W2597476871 hasConcept C2778830669 @default.
• W2597476871 hasConcept C2778963024 @default.
• W2597476871 hasConcept C2780739268 @default.
• W2597476871 hasConcept C2781433595 @default.
• W2597476871 hasConcept C2994587330 @default.
• W2597476871 hasConcept C3019894029 @default.
• W2597476871 hasConcept C50382708 @default.
• W2597476871 hasConcept C71924100 @default.
• W2597476871 hasConcept C72563966 @default.
• W2597476871 hasConceptScore W2597476871C121608353 @default.
• W2597476871 hasConceptScore W2597476871C126322002 @default.
• W2597476871 hasConceptScore W2597476871C143998085 @default.
• W2597476871 hasConceptScore W2597476871C2776131300 @default.
• W2597476871 hasConceptScore W2597476871C2777701055 @default.
• W2597476871 hasConceptScore W2597476871C2778830669 @default.
• W2597476871 hasConceptScore W2597476871C2778963024 @default.
• W2597476871 hasConceptScore W2597476871C2780739268 @default.
• W2597476871 hasConceptScore W2597476871C2781433595 @default.
• W2597476871 hasConceptScore W2597476871C2994587330 @default.
• W2597476871 hasConceptScore W2597476871C3019894029 @default.

• next